



# GUJARAT THEMIS BIOSYN LIMITED

**CIN: L24230GJ1981PLC004878**

REGD. OFFICE & FACTORY : 69/C GIDC INDUSTRIAL ESTATE,

VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL : 0260-2430027 / 2400639

E-mail: [hrm@gtbl.in.net](mailto:hrm@gtbl.in.net)

**GTBL: CS: BSE-CORR/2023-24**

**10<sup>th</sup> February, 2024**

**The Manager,**

Corporate Relationship Department,

**BSE Limited**

Floor 25, Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400001.

Scrip Code – 506879

Dear Sir / Madam,

**Sub: Outcome of Board Meeting under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Meeting Commencement time : 10:00 A.M.

Meeting Conclusion Time : 11.00 A.M.

Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Saturday, 10<sup>th</sup> February, 2024, has inter-alia approved the following:

a) The Unaudited Standalone Financial Results for the Quarter ended 31<sup>st</sup> December, 2023.

A copy of Unaudited Standalone Financial Results for the Quarter ended 31<sup>st</sup> December, 2023 together with Limited Review Report is enclosed herewith.

b) Declaration of an Interim Dividend for the Financial Year 2023-24 of ₹ 0.75/- (Rupee Seventy-Five paise only) per equity share having face value of ₹ 1/- i.e. 75.00% aggregating to ₹ 5,44,82,632.50/- (Rupees Five Crore Forty-Four Lakhs Eighty-Two Thousand Six Hundred and Thirty-Two and Fifty Paise only)

c) The Record Date for the purpose of interim dividend is 22<sup>nd</sup> February, 2024.

This may be taken as compliance under the Listing Regulations.

Thanking you,

Yours faithfully

For **GUJARAT THEMIS BIOSYN LIMITED**

**Rahul Soni**

**Company Secretary & Compliance Officer**

Encl: As above

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2023

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2023 (Unaudited)	30.09.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.03.2023 (Audited)
I	Income from operations	3,885.89	3,965.35	2,816.50	12,810.04	12,080.03	14,897.29
II	Other Income	100.40	100.07	180.63	307.94	462.52	602.38
III	<b>Total Income (I+II)</b>	<b>3,986.29</b>	<b>4,065.42</b>	<b>2,997.13</b>	<b>13,117.98</b>	<b>12,542.55</b>	<b>15,499.67</b>
IV	Expenditure						
	(a) Cost of raw material consumed	635.21	676.29	743.75	1,952.83	2,277.36	2,973.03
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of Finished Goods, Work-in-Progress and Stock in Trade	60.70	120.49	(544.37)	889.58	174.37	(323.54)
	(d) Employee benefits expense	267.95	250.05	194.87	725.76	560.17	774.71
	(e) Finance Cost	7.88	5.07	7.10	15.46	17.58	20.07
	(f) Depreciation and Amortisation expenses	97.81	88.40	65.81	261.11	180.65	257.57
	(g) Other Expenses						
	i) Stores and spares	108.02	110.83	133.66	312.37	353.05	428.61
	ii) Power	495.46	515.05	447.56	1,513.37	1,335.16	1,788.27
	iii) Fuel	129.34	136.18	188.59	410.97	577.65	748.23
	iv) Water	31.31	28.12	26.48	92.58	77.36	104.05
	v) Other expenditure	383.33	446.37	414.87	1,105.38	795.81	982.17
	<b>Total Expenses</b>	<b>2,217.01</b>	<b>2,376.86</b>	<b>1,678.33</b>	<b>7,279.42</b>	<b>6,349.17</b>	<b>7,753.19</b>
V	<b>Profit/(Loss) before Exceptional Items and Tax (III-IV)</b>	<b>1,769.28</b>	<b>1,688.56</b>	<b>1,318.80</b>	<b>5,838.56</b>	<b>6,193.38</b>	<b>7,746.48</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit/(Loss) before Tax (V-VI)</b>	<b>1,769.28</b>	<b>1,688.56</b>	<b>1,318.80</b>	<b>5,838.56</b>	<b>6,193.38</b>	<b>7,746.48</b>
VIII	Tax expenses						
	(a) Current Tax	460.82	423.16	320.36	1482.96	1540.71	1924.06
	(b) Deferred Tax	7.20	11.06	17.70	27.84	25.00	25.54
IX	<b>Net Profit/(Loss) after tax (VII-VIII)</b>	<b>1,301.26</b>	<b>1,254.34</b>	<b>980.74</b>	<b>4,327.76</b>	<b>4,627.67</b>	<b>5,796.88</b>
X	Other Comprehensive Income						
	(a) Items that will not be reclassified to Profit or Loss						
	(i) rereasurement of defined benefit plans;	2.02	2.02	(2.70)	6.07	(8.09)	8.09
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	(0.53)	(0.53)	0.70	(1.58)	2.10	(2.10)
	(b) Items that will be reclassified to Profit or Loss						
	(i) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>1,302.75</b>	<b>1,255.84</b>	<b>978.76</b>	<b>4,332.25</b>	<b>4,621.69</b>	<b>5,802.87</b>
XII	Paid-up equity share capital	726.44	726.44	726.44	726.44	726.44	726.44
XIII	Other Equity						14,188.15
XIV	<b>Earnings Per Share (Basic and Diluted)</b>	<b>1.79</b>	<b>1.73</b>	<b>1.35</b>	<b>5.96</b>	<b>6.37</b>	<b>7.98</b>



**Notes:**

- 1 The financial results for the Quarter and Nine months ended December 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 10, 2024.
- 2 The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 During the quarter ended December 31, 2023, the company on October 10, 2023 ("Record Date"), sub-divided/split of existing Equity Share of the Company from 1 (One) Equity Share having face value of Rs. 5/- (Rupees Five only) each fully paid-up, into 5 (Five) Equity Shares having face value of Re. 1/- (Rupee One only) each fully paid-up. Accordingly, earnings per share of comparative periods presented has been calculated based on number of shares outstanding in respective periods, as increased by sub-divided/split of shares.
- 5 The Board has declared an Interim dividend for financial year 2023-24 @Re. 0.75 paise per equity share on the face value of Re. 1/-.
- 6 Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.



For GUJARAT THEMIS BIOSYN LIMITED

Dr. DINESH PATEL  
Chairman  
DIN : 00033273

Place: Mumbai  
Date : 10-02-2024

**Independent Auditor's Review report on Quarterly Unaudited Financial Results and Year to Date Financial Results of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Review report to  
The Board of Directors  
GUJARAT THEMIS BIOSYN LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended December 31, 2023 and year to date from April 1, 2023 to December 31, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For GMJ & Co**  
Chartered Accountants  
FRN: 103429W

*Amit Maheshwari*

CA Amit Maheshwari

Partner

M. No.: 428706

UDIN: 244287 06 RkFN JF 6317



Place : Mumbai

Date : February 10, 2024